{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116799","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.879326+00:00","generated_at":"2026-06-21T23:14:01.032926+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel Q3 net loss $41.8M; revenue $137K; IGALMI launch progress with 70-rep sales force by Dec 1","bullets":["Net loss of $41.8M for Q3 2022 vs $26.8M loss in Q3 2021; revenue $137K from early product trials.","Cash and equivalents $232.3M; operating cash used $31.5M in quarter.","IGALMI commercial: signed largest GPO covering ~50% target beds; expanding sales force to 70 reps by Dec 1 covering 1,700 hospitals.","Pipeline: TRANQUILITY II and SERENITY III top-line data expected 1H 2023 for agitation indications.","Phase 1 MDD program completed multiple daily dosing cohorts; top-line results expected 1H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116799","json":"https://secwatch.observer/filing/0001104659-22-116799.json","markdown":"https://secwatch.observer/filing/0001104659-22-116799.md","text":"https://secwatch.observer/filing/0001104659-22-116799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922116799/0001104659-22-116799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922116799/tm2230135d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:14:01.032926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a14539bd02e7040a6d46e96502df28bb2f3e0b3b","claim":"BioXcel Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on key strategic initiatives.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922116799/0001104659-22-116799-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}